Company's stock plunges with rest of marketYou never know with the stock market. Ultrasound vendor Acuson was a victim of the market's quixotic nature on Oct. 23, when shares of the Mountain View, CA, company plummeted 22%, the day after the
Company's stock plunges with rest of market
You never know with the stock market. Ultrasound vendor Acuson was a victim of the market's quixotic nature on Oct. 23, when shares of the Mountain View, CA, company plummeted 22%, the day after the vendor reported healthy growth in revenues and a sharp rise in net income for its third quarter (end-September). The third-quarter numbers exceeded Wall Street estimates, but the financial community may have been reacting to predictions by Acuson executives that future earnings could be affected by softness in the international market.
For the quarter, Acuson posted a 7% increase in quarterly revenues, while net income almost tripled. The vendor reported revenues of $100.1 million for the period, compared with $93.3 million in the same period of 1996. Net income was $4.5 million, compared with $1.6 million in the third quarter of 1996. Earnings per share were 15, compared with analysts' estimates of 14.
The company attributed the growth in revenues and net income to the success of its new Sequoia and Aspen scanners. In particular, the company cited the signing in August of a sole-source contract to supply radiology scanners to Kaiser Foundation Health Plan.
Despite the success of Sequoia and Aspen, Acuson executives said that the international market was showing signs of weakness. Incoming international orders had been impacted by softness in selected European and Asian markets, as well as the strong U.S. dollar. Acuson expects these trends to continue at least through the end of the year, company executives said in a conference call on Oct. 22.
"We discussed the fact that there has been some weakness in international markets, which has been observed by everyone over the last month or so," said Stephen Johnson, Acuson CFO. "Based on those comments, some analysts following the company reduced their expectations of future earnings."
Acuson shares began falling on the first day of trading after the results were released, dropping $5.81 to close at $20.88 on Oct. 23. The fact that the U.S. stock market suffered a sharp decline that day, which was triggered by a major drop on the Hong Kong stock exchange, didn't help.
"We had the misfortune of (releasing earnings) on a day when markets around the world were falling," Johnson said.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.